• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Molecular Partners

edit

Molecular Partners AG, a biotechnology company, engages in the discovery and development of Designed Ankyrin Repeat Proteins (DARPins) based on the designed repeat protein technology. The company focuses on therapeutic, diagnostic, and biotechnological applications of DARPins. DARPins are binding proteins that show activity against various disease targets, including cell surface receptors, cytokines, proteases, kinases, and viral coat proteins. The company was incorporated in 2004 and is based in Zurich, Switzerland.

Recent Milestones

edit

• 
  Molecular Partners — Allergan snags rights to retinal disease drug in $420M pact (5/4/11)
  Posted 5/4/11 at 6:17pm via fiercebiotech.com
• 
  Molecular Partners received $44.2M in Series B funding. (12/16/09)
  Posted 12/18/09 at 1:24am via dowjones.com
• 
  Molecular Partners received $15.6M in Series A funding. (8/14/07)
  Posted 3/13/10 at 3:10am via molecularpartners.com
• 
  Molecular Partners added Christian Zahnd as CEO.
  Posted 12/18/09 at 1:24am
• 
  Molecular Partners added Andreas Emmenegger as CFO.
  Posted 12/18/09 at 1:24am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/18/09

Sources

1. MOLECULAR PARTNERS SECURES $15.56 million IN SERIES A FINANCING (molecularpartners.com) [edit]
2. Swiss Protein Therapy Co. Molecular Partners Pulls In $44M Series B (fis.dowjones.com) [edit]
Allergan snags rights to retinal disease drug in $420M pact (fiercebiotech.com) [edit]